. Author manuscript; available in PMC: 2008 Jun 1.

Published in final edited form as: J Pediatr. 2007 Jun;150(6):623–626. doi: 10.1016/j.jpeds.2007.01.049

Table 2.

Differences in characteristics between children with mild disease, severe disease and severe disease taking hydroxyurea, in subset of children with HgbSS. Results are odds ratios (OR) and 95% Confidence Intervals for having a reduced functioning allele or activity score ≤ 1.5 compared to mild disease.

	Mild (n = 17)	Severe (n = 30)	Severe taking Hydroxyurea (n=22)
Mean age (s.d.)	10.1 (4.1)	12.6 (3.9)^*	12.6 (3.9)^*
Female	8 (47%)	21 (70%)	15 (68%)
Possessed a reduced functioning allele	9 (53%)	21 (70%)	19 (86%)^*
2D6 Activity score ≤ 1.5	16/36 (44%)	20 (67%)	18 (82%)^*
O.R. (95% CI) for having reduced functioning allele	referent	2.1 (0.6 – 7.1)	5.6 (1.2 – 26.4)^*
O.R. (95% CI) for activity score ≤ 1.5	referent	2.3 (0.7 – 7.6)	5.1 (1.2 – 21.4)^*

Bold indicates significantly different from “Mild”; p < 0.05